Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
Of course Africa is ready for PrEP!

Whether or not Africa is ready for PrEP interests me because of several underlying assumptions in some of the answers about how we define Africa. Africa’s MSM, Africa’s people who engage in anal sex and Africa’s public health prevention campaigns have been desperately in need of new HIV prevention options for a very long time.

Published
12 April 2011
From
Incidence 0
PrEP: A Possible Approval Like No Other

While I agree that PrEP should be considered as an option in the HIV prevention toolkit and would ultimately support an effort by Gilead to expand Truvada's labeling to include PrEP--should the company petition the FDA for approval--I am also of the mind that a green light from the FDA should not be met with the rush-to-treatment that typically follows approval of a drug. 

Published
31 March 2011
From
Poz
What Lies Ahead: An Activist's View of Promising HIV Treatment Research

After attending the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston, Mass., and following different areas of research, I decided to write down a list of advancements that really thrill and energize me as an educator and research advocate.

Published
31 March 2011
From
The Body
Is Africa Ready for PrEP?

Shouldn’t one of the main concerns be to ensure that the drug would be available for those who need it worldwide? With an estimated cost of the Truvada put at $36 a day or up to $14,000 a year, what are the chance of millions of poor people in Africa to access what might be a life saving drugs?

Published
29 March 2011
From
Incidence 0
PrEP: Don’t fear progress in HIV prevention

The paid advertisement in this issue of GA Voice correctly reminds us that “there is no magic pill” to prevent HIV infection. Unfortunately, the ad is part of a campaign to convince the FDA not to review, and Gilead Sciences not to submit, data to support approval of Truvada for HIV prevention.

Published
21 March 2011
From
The Georgia Voice
ACT NOW: Choice in HIV Prevention: Let FDA Look at the PrEP Data

Like many of you, we were intrigued by the results of the iPrex trial of pre-exposure prophylaxis (PrEP) that came out late last year.  The U.S. Food and Drug Administration (FDA) should review those results and determine if PrEP is safe and effective enough to be approved for widespread use. Unfortunately, a key HIV health care provider is asking the FDA to deny this choice to gay men and transgender people across the United States.  Sign this letter as individuals and/or organizations to support immediate FDA review of PrEP.

Published
17 March 2011
From
HIV Prevention Justice Alliance
AHF to Gilead: “No Magic Pill” Ads Warn against AIDS Drug as HIV Prevention

AHF’s Print Ad Campaign, “There is No Magic Pill,” to Run in Gay Magazines & Newspapers in a Dozen Cities Nationwide; AIDS Group Questions Gilead’s Plans for FDA Approval of Truvada for ‘Pre-Exposure Prophylaxis’ Drug Giant’s Move for FDA Approval beyond AIDS Treatment Follows Study Involving 2,500 Gay Men That Showed a 44% Effectiveness Rate in Preventing HIV Transmission among People Who Took Truvada as Form of Prevention.

Published
09 March 2011
From
Yahoo News
Gilead's $12000-a-Year HIV Prevention Pill Fails to Win Physician Support

While study findings show the drug prevents HIV in non-infected, sexually active gay men, doctors say they're wary about giving healthy people a $12000-a-year medicine that has side effects that can include nausea and kidney damage, and may not be used ...

Published
28 February 2011
From
Bloomberg
Concept paper on medicines to prevent HIV infection released for public consultation

The European Medicines Agency has released a concept paper on the development of medicines to prevent HIV infection for a two-month public consultation period.

Published
27 February 2011
From
European Medicines Agency
Ten Key Global Policy Developments Concerning MSM & HIV in 2010

The year 2010 was very important for activists focused on the health and human rights of MSM.  There were a number of key developments – both positive and negative – that made a significant impact on the global advocacy landscape. 

Published
18 February 2011
From
The Global Forum on MSM and HIV

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.